FDA grants accelerated approval to Rybrevant Faspro for head and neck cancerNov 5Regulatory decisionamivantamab and hyaluronidase-lpujamivantamab-vmjw
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
FDA clears atezolizumab combo for Stage III dMMR colon cancerOct 8Regulatory decisionatezolizumabatezolizumab and hyaluronidase-tqjs
Sign inSign in